Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abacavir, abatacept, accident, accomplished, Actemra, adult, airway, ALT, ambulatory, Amgen, anin, antibody, Avanir, Beth, Bink, biomarker, Boerhinger, brecanavir, bronchial, brought, Bucknell, budgetary, Cantley, carbamazepine, category, cessation, chain, classifed, Columbia, compromise, Cornell, corrector, creatinine, denufosol, designee, die, digital, diminished, disability, displayed, dispoproxil, disruption, diversification, DMARD, drop, drugable, Eastern, Edmund, education, educational, elderly, electrocardiogram, electrocardiographic, English, enzymology, epithelial, erlotinib, Error, EULAR, exempt, exhange, facilitate, footage, France, frequency, Fridericia, FSP, fumerate, Garrison, gastrointestinal, gyrA, gyrB, harm, HARMED, highest, Holland, Idenix, imatinib, impossible, impractible, improper, inconclusive, Ingleheim, inhaled, input, Inspire, Iowa, IRB, irreversible, Israel, Italy, itching, Johanna, kinetic, labor, landscape, largest, lt, lymphoma, managerial, mandatory, markedly, Messina, mesylate, methodology, mitigate, MMA, modern, Modernization, modification, monoclonal, morbidity, morning, mortality, msec, myeloma, neopterin, neutropenia, nonsense, Northeastern, Orencia, Organizational, outsource, oversee, parC, parE, plasma, political, pollution, polymerase, Predix, predominated, Premature, Princeton, proceed, Prograf, Programme, propriety, PTC, Publishedin, QTcF, quantitation, Quinn, rash, raw, RBV, recommend, recurrent, redefine, reducedin, reevaluate, relaxation, remuneration, rentable, residual, responsiblity, retonavir, retrospective, risky, Rituxan, rituximab, salt, Sandoz, secret, shipping, shorten, Sidney, simulation, simultaneously, skin, Southwestern, Spain, subtype, supplier, surface, suspension, swollen, syndrome, tablet, tableting, Takeda, TaqMan, tenofovir, tetrasodium, TheraCLEC, Theravance, tocilizumab, TolerRx, tort, Transduction, transmembrane, ultrasensitive, unanticipated, uncovered, unexpected, unforeseen, unqualified, upper, valopicitabine, variant, Vassar, VaxGen, vendor, Vitae, vulnerable, water, widespread, workplace
Removed:
activate, activation, additive, addressing, adequately, affiliated, Africa, Ahab, alanine, alpha, aminotransferase, Anthony, antiretroviral, artery, asthma, auditing, augmented, Berkeley, BMS, carbamezepine, cascade, CDC, Chair, characteristic, collaborated, collectively, complement, complementary, concert, conclusion, conflict, conformation, congestive, consolidation, consultant, context, contrast, convenient, CPA, created, Crohn, cycle, deciding, deleted, Dermatology, description, designate, detecting, determination, discretion, distort, District, druggable, dupont, earn, eliminate, enabled, enabling, encountered, entail, equally, essentially, establishment, excluded, executed, expectation, exploratory, expose, faculty, forgive, Fritz, GFP, GSK, guanine, helicase, HMR, impacted, indirectly, inhibiting, initiating, insight, internationally, ischemia, ix, lawsuit, ligand, lipid, MA, mechanism, mediated, merged, metabolite, middle, month, myocardial, native, NEAT, negotiate, nelfinavir, neurophilin, Neuroscience, newer, OA, offered, operational, optical, optional, overlapping, Oxfordshire, Pamela, participated, persist, pharmacological, phenomenon, positioned, postdoctoral, preferentially, progressive, promote, prove, Prozei, quantify, Radcliffe, regeneration, released, remained, removal, resignation, resistance, responded, restructured, satisfactory, Sato, selectively, Serono, serve, settlement, shortly, SOLO, sought, Stanford, stroke, studied, subunit, supplement, Taisho, throughput, tied, trend, triple, uncontrolled, underwent, undesirable, unit, unresponsive, unspecified, validate, variable, vi, Vicki, vii, viii, vying, West
Filing tables
Filing exhibits
VRTX similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the "Company"), does hereby certify, to such officer's knowledge, that:
The Annual Report on Form 10-K for the year ended December 31, 2005 (the "Form 10-K") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: March 16, 2006 | ||
/s/ JOSHUA S. BOGER Joshua S. Boger Chairman, President and Chief Executive Officer | ||
Date: March 16, 2006 | ||
/s/ IAN F. SMITH Ian F. Smith Executive Vice President and Chief Financial Officer |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
SECTION 906 CEO/CFO CERTIFICATION